The Strategic Integration of Kampo Medicine: A Long-Term Driver of Growth in the Japan Cancer Supportive Care Market
Description
This blog post explores the unique role and market dynamics of Kampo medicine, the traditional Japanese herbal therapy, within the broader context of the Japan Cancer Supportive Care Market, analyzing its use alongside conventional treatments and the factors influencing its long-term market trajectory.
Kampo medicine represents a distinct and culturally significant component of the oncology supportive care landscape in Japan. Unlike in many Western markets, Kampo preparations are widely approved under national medical insurance and are often prescribed by medical doctors. This dual-system of care, where patients can access both Western and traditional Japanese medicine simultaneously, underpins its strategic importance. The increasing focus on patient quality of life (QoL) and the need to manage challenging side effects of chemotherapy, such as fatigue, anorexia, and peripheral neuropathy, position Kampo as a valuable complementary therapy.
Recent nationwide analyses show that Kampo medicines have a significant presence, with a substantial percentage of cancer patients being prescribed them for supportive care, even though a slight decrease in its usage trend was noted from 2015 to 2021, possibly due to a call for stronger clinical evidence. Nevertheless, the continuous research and publication of highly reliable clinical studies on its effectiveness in alleviating side effects (e.g., Rikkunshito for anorexia/cachexia, Hochuekkito for fatigue, and Goshajinkigan for peripheral neuropathy) contribute to its sustained relevance. Major market players like Tsumura & Co. actively focus on cancer supportive care as a priority area, further solidifying the market's structure and the long-term prospects for this traditional treatment modality. The ongoing integration and generation of evidence will be critical for Kampo medicine to maintain and expand its influence in the evolving market.